The Maryland Development Center (MDC) is a startup studio in downtown Baltimore founded by surgeons and biomedical engineers to accelerate the development and commercialization of health technologies. We lay the foundation that transforms ideas into tangible solutions, while emphasizing early technical development to prepare companies to seek funding. We will describe the MDC model, company highlights, and opportunities to get involved as we expand both our technical and business operations.
About the speakers:
Dr. Nao J. Gamo
is a Co-founder and Chief Executive Officer of NeuroSonics Medical, Inc., a Johns Hopkins University spinoff in which her team is developing a novel ultrasound transducer for minimally invasive neurosurgery. Before becoming an entrepreneur in 2017, she spent over ten years as an academic researcher in neuroscience and psychiatry. She completed undergraduate degrees in Brain and Cognitive Sciences and Music from the Massachusetts Institute of Technology, a PhD in Neurobiology from Yale University, and a postdoctoral fellowship in the Molecular Psychiatry Program at Johns Hopkins University.
Dr. Gil Blankenship
is the CEO of the Maryland Development Center. Dr. Blankenship has founded several high technology companies, including Techno-Sciences, Inc. (Maryland High Tech Company of the Year 2010, Deloitte Fast 500 2009-2011), the world leader in satellite aided search and rescue with installations in 30 countries. The Tech Council of Maryland named Dr. Blankenship an International Business Leader of the Year in 2008 for his work at TSi. He is also co-founder and Director of TRX Systems, Inc. (Global Security Challenge Winner 2009, Tibbetts Award 2012, Edison Award 2015, Motorola Ventures investment 2013), the premier company in personnel tracking and mapping. TRX has 29 US patents including 25 international patents issued or pending.
Dr. Stephen Restaino
is a biomedical engineer with a passion for developing portable technologies that can deliver advanced medical care in any environment. In the fall of 2017, Stephen earned a PhD from the University of Maryland, College Park for work on portable biosensing technologies. His graduate research led to 3 patent applications, multiple academic publications, and presentations at international conferences. Prior to graduate school, he worked at the FDA studying physiological and regulatory implications of implantable nerve stimulators. His efforts garnered recognition as a “Leader of Tomorrow” in biotechnology by the Biohealth Capital Region Forum. There he was a finalist in the inaugural pitch competition.